Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Exploring the market potential of Revance's RT002 botulinum toxin injectable for the treatment of glabellar (frown) lines

Ticker(s): RVNC, AGN, NESN.VX

Who's the expert?

Name: Dr Shashi Kusuma - MD

Institution: Suria Plastic Surgery

  • Plastic surgeon in private practice; Board Certified in Otolaryngology & Plastic Surgery.
  • Performs 15 to 20 botulinum toxin injections a week; other procedures include facial aesthetics including fillers of all types, fat grafting, facelifts, laser resurfacing, and breast augmentation/reconstruction.
  • Previously served as a Staff Surgeon in the Department of Plastic and Reconstructive Surgery at the Cleveland Clinic Foundation.

Interview Questions
Q1.

Please describe your clinical practice, what is the most often botulinum toxin that you use, what do patients prefer best, and tell us how well could a new product fit into the market?

Added By: c_admin
Q2.

The company cites that RT002 maintains benefit for 5 months, compared to other botulinum toxin injections available on the market benefit of 3 months.

  • the 40U dose of daxibotulinumtoxin A (RT002) showed a greater response rate and a longer duration of response vs 20U onabotulinumtoxinA (median of 24 weeks vs 19 weeks; p = .030)
  • Judging from your clinical experience, is this true, especially considering how age, skin tan, face structure and other factors can affect the time span of the treatment?

Added By: c_admin
Q3.

If the Phase 3 data turns out positive, the company wants to file for a 6-month duration label with the FDA. Do you think this is achievable, or is it over-reaching?

  • Would the twice per year procedure for returning patients be more convenient for you and your patients?

Added By: c_admin
Q4.

The long-term safety trial is expected to enroll approximately 1,500 subjects, and a subject may be on trial for a maximum of 84 weeks. Do you foresee any adverse effects that might come with the prolonged exposure to the toxin, such as ptosis, pain, rashes, infection, muscle damage or spasms, that could endanger the approval of RT002?

Added By: c_admin
Q5.

More than twice as many RT002 40U and 60U subjects in the BELMONT Study maintained none or mild wrinkles on the IGA-FWS scale as compared to BOTOX Cosmetic at Week 16 (p ≤ 0.002). Is this a strong argument in itself to make the switch from botox to RT002 tempting? And what other factors could be influencing you to make the switch?

Added By: c_admin
Q6.

How different is the dosing between RT002 and BOTOX? I know dosing differences between BOTOX and DYSPORT were played up by Allergan calling switching to DYSPORT “like learning a different language”

Added By: c_admin
Q7.

Could a company like Revance compete vs. the other toxins without a full line of products? How important are loyalty programs in this space and can the maker of RT002 do anything to compete on this plane?

Added By: c_admin
Q8.

 In your opinion, how important is RT002’s formulation that combines proprietary peptide that purports to help toxin’s effect  last longer ? 

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.